Skip to main content

Table 2 Common areas of loss, gain, deletion and amplification identified by aCGH in MDA-MB-231 PACR, ZR75-1 PACR and ZR75-1 DOCR at the two resistance levels 25nM and 50nM when compared to the native cell line

From: Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance

Cell line Extending loss Extending gain Deletion Amplification
231 PACR 1p36.13-q44 2p25.3-23.3 6p21.1 6p21.1
  6p25.3-q12 3p24.3-q13.3 2q13 1q32.3
8p 4p16.1-q12 15q11,2 4q21.21-21.22
10p 5q14.3-q31.1 16 q11.2 8p12, 8p11.21
19q 8q21.13-24.3   11q13.2
X Chr. 11q15.1-q25   12q14.1
centromeric 12   12q14.2
centromeric 14   12q15
15q11.2
15q22.2-q22.3
ZR75 PACR 1q None None None
  3p    
  7q    
  12p    
  15p    
  16q    
ZR75 DOCR 7q None None None
  12p    
  16q